Introduction: Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys andnerves.A majority of affected patients living in low-and middle-income strata of the society.Today, a substantial number of oral anti-diabetic drugs are available for the treatment of Type 2 diabetes mellitus. But, there are numerous brands available for each of the individual oral anti-diabetic drug. Aims and objectives: Our study aims to find out the variation in prices of different brands of the single oral hypoglycemicdrug by calculating percent cost variation, cost ratio and the same in terms of Defined Daily Dose (DDD) as well. Methodology : The information about the prices of various brands of 19 single oral Anti-diabetic drugs were obtained.The cost of drugs were taken from the latest issue of (CIMS) Current Index of Medical Specialities April-July 2023, Drug Today April July 2023 ,1mg online site. Cost ratio and Cost percent variation, was calculated using Microsoft Excel Software .Drugs belonging to same as well as different groups of anti-diabetic drugs were compared and analysed. Analysis and results: Among all oral anti- diabetic drugs,glibenclamide5 mg (900%) was found to have highest cost ratio and cost variation and canagliflozin 100 mg(10.57 %) was found to have lowest.Amidst DP44 inhibitors class of Oral Hypoglycemic Drugs, Sitagliptin 25 mg (506.67 %) has highest cost variation and saxagliptin 2.5 mg (43.16 %) showed lowest. In the group of sulfonylurea group of drugs,Glibenclamide 5 mg (900 %)& Glimepiride 0.5mg(27%) showed highest and lowest cost variation respectively. Similarly,among Thiazolidinediones,the highest cost variation was with Pioglitazone 15 mg (350 %) whereas rosiglitazone 4 mg(78%) showed the lowest.alpha glucosidase inhibitors of oral antidiabetic drugs. Voglibose 0.2mg (242.77%)showed highest and acarbose 50 mg (26.77 % )showed lowest cost variation. Conclusion: Our study reveals that The cost variation among the different brands of the same drug is very high. This imposes a great economic burden on the patients and adversely affects compliance. Thus, our study will provide an insight to the prescriber and Drug Price control authorities to minimize the financial burden on the patients, and lead to betterment of patient care in the country.